LOS ANGELESResearchers at Cedars-Sinai Medical Center’s
Maxine Dunitz Neurosurgical Institute are conducting a clinical trial of
temozolomide (Temodar) in patients with mixed gliomas or oligodendroglial
tumors. They expect to enroll about 60 patients over a 30-month period.
According to Paul Zeltzer, MD, lead investigator, when mixed
glioma brain tumors are treated with procarbazine, CCNU, and vin-cristine (PCV)
after surgery and radiotherapy, 7-year survival rates are 50% to 70%. However,
longer-term survival rates remain low, since the tumors tend to return.
The researchers hope that by treating newly diagnosed patients
first with temozolomide, then with PCV, tumor growth will be arrested earlier
and recurrence rates will be reduced. Patients will receive temozolomide
capsules daily for 6 weeks, followed by a 4-week rest period. Cycles may be
repeated once, depending on tumor response. For information, call the
Cedars-Sinai Maxine Dunitz Neurosurgical Institute at 310-423-7900.